IDH1 and central nervous system cancer: The impact of IDH mutations in gliomas was found to apparently sensitize the tumors to radio/chemotherapy, as no differences were found in the progression-free survival between IDH-mutant and IDH-WT gliomas if patients were not given radio/chemotherapy from the time of surgery to the time of disease progression (Hartmann et al., 2011; Ahmadi et al., 2012).